Twist Bioscience Corporation (NASDAQ:TWST) marked $46.83 per share on Thursday, up from a previous closing price of $46.01. While Twist Bioscience Corporation has overperformed by 1.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TWST fell by -61.07%, with highs and lows ranging from $139.99 to $25.07, whereas the simple moving average fell by -22.20% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Sponsored
On March 02, 2022, Cowen started tracking Twist Bioscience Corporation (NASDAQ: TWST) recommending Outperform. Goldman Initiated an Neutral rating on June 04, 2021, and assigned a price target of $110. Piper Sandler initiated its ‘Overweight’ rating for TWST, as published in its report on April 12, 2021. JP Morgan’s report from February 05, 2021 suggests a price prediction of $100 for TWST shares, giving the stock a ‘Underweight’ rating. Evercore ISI also rated the stock as ‘In-line’.
Analysis of Twist Bioscience Corporation (TWST)
Further, the quarter-over-quarter increase in sales is 54.20%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Twist Bioscience Corporation’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -28.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.24M can be a very valuable indicator of volatility for TWST stock. On a monthly basis, the volatility of the stock is set at 8.29%, whereas on a weekly basis, it is put at 6.13%, with a gain of 6.58% over the past seven days. Furthermore, long-term investors anticipate a median target price of $48.50, showing growth from the present price of $46.83, which can serve as yet another indication of whether TWST is worth investing in or should be passed over.
How Do You Analyze Twist Bioscience Corporation Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.30%. This can enable you to see the extent to which executives own the company’s stock.
Are institutional investors increasing their holdings in TWST shares?
The recent increase in stakes in TWST appears to be a result of several institutional investors and hedge funds increasing their positions. Fidelity Management & Research Co’s position in TWST has increased by 171.84% in the first quarter. The company now owns 6,565,410 shares of the stock, with a value of $229.53 million, following the purchase of 4,150,198 additional shares during the last quarter. ARK Investment Management LLC made another increased to its shares in TWST during the first quarter, upping its stake by 19.06%. During the last quarter, the company picked up 1,003,466 additional shares for a total stake of worth $219.12 million, bringing number of shares owned by the company to 6,267,721.
During the first quarter, Capital Research & Management Co added a 273,148 position in TWST. The Vanguard Group, Inc. purchased an additional 0.45 million shares in the last quarter, increasing its holdings by 10.75%, now holding 4.64 million shares worth $162.35 million. At the end of the first quarter, BlackRock Fund Advisors increased its TWST holdings by 12.46% and now holds 3.74 million TWST shares valued at $130.67 million with the added 0.41 million shares during the period.
